SAE, n (%) | Daclizumab 150 mg SC |
---|---|
(N = 410) | |
Any SAE | 105 (26) |
MS relapse | 47 (11) |
Increased hepatic enzyme | 3 (<1) |
Pneumonia | 3 (<1) |
Ulcerative colitis | 3 (<1) |
Urinary tract infection | 3 (<1) |
Bronchitis | 2 (<1) |
Intervertebral disc disorder | 2 (<1) |
Lower limb fracture | 2 (<1) |
Lymphadenopathy | 2 (<1) |
Urticariab | 2 (<1) |